Celsion Corp
Fechado
0
Visão Geral
Variação de preço das ações
24h
Mín
Máximo
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +646.19% upside |
Celsion Corp Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Celsion Corp Previsão
Preço-alvo
By TipRanks
646.19% parte superior
Previsão para 12 meses
Média 15.67 USD 646.19%
Máximo 25 USD
Mínimo 10 USD
Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Celsion Corp - Dist nos últimos 3 meses.
Informação Financeira
$
Sobre Celsion Corp
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
